Clinical Trial Update: Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated oral BIBF 1120 (nintedanib) in combination with docetaxel and prednisone in patients with hormone-refractory prostate cancer; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• BIBF 1120 (nintedanib)
• DOCETAXEL (DOCETAXEL)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Prostatic Neoplasms | Phase 1 | Status: COMPLETED